immunology

Pharma

Galderma doubles Nemluvio peak sales outlook to $4B-plus

The update follows what Galderma’s CEO described as an “outstanding launch trajectory” for the Dupixent competitor in its first full year on the market.

Angus Liu Mar 5, 2026 11:20am

Sanofi inks $1.5B deal for Sino Biopharm's novel asset

Mar 4, 2026 3:00am

AbbVie snaps up device plant amid broader $10B US investment

Jan 12, 2026 9:17am

cost cutting restructuring savings reduce spend

InflaRx charts layoffs, cost cuts to lift lead asset's prospects

Jan 8, 2026 11:03am

An arrow incrementally going up stairs before pointing straight up Blue background

Regeneron, AZ regulatory plans bolstered by phase 3 wins

Nov 7, 2025 2:00pm

Massachusetts Massachusetts flag MA MA flag

AbbVie unveils $70M expansion in MA

Oct 1, 2025 9:05am